Triple-Negative Breast Cancer (TNBC)

Introduction to Triple-Negative Breast Cancer (TNBC)

TNBC accounts for approximately 15-20% of all breast cancer cases and is more prevalent in younger women, African American women, and those with BRCA1 mutations. Clinically, TNBC is associated with an increased risk of recurrence, metastatic disease, and shorter overall survival compared to other breast cancer subtypes. This is largely due to the absence of targeted therapies, such as endocrine therapy and HER2-directed agents, which have revolutionized the treatment of hormone receptor-positive and HER2-positive breast cancers, respectively.

Fig.1 Classifcation and therapeutic options for TNBC. (Li Y., et al. 2022)

Therapy Development for Triple-Negative Breast Cancer (TNBC)

TNBC is a highly heterogeneous cancer with specific mutations and aberrant activation of signaling pathways. Therefore, targeted therapies (e.g., therapies targeting DNA repair pathways, androgen receptor signaling pathways, and kinases) are promising options for the treatment of TNBC. In addition, immunotherapy has been shown to improve overall survival and response rates in TNBC. We summarize important recent advances in therapeutic strategies based on the molecular subtypes of TNBC.

Our Services

At Alfa Cytology, we offer a comprehensive suite of preclinical services to support the development of novel TNBC therapies. Our state-of-the-art facilities and experienced team of scientists provide a wide range of in vitro and in vivo capabilities, including:

TNBC Therapy Development Platforms

Disease Models of TNBC

Through rigorous research and collaboration with experts in the field, we aim to identify novel therapeutic targets and develop innovative drugs that can effectively treat TNBC while minimizing side effects. Our company's expertise in drug development, including preclinical research and model development, allows us to accelerate pharmaceutical companies' research and development.

TNBC Cell Lines	Animal Models of TNBC
Hs578T Cell Lines MDA-MB-231 Cell Lines MDA-MB-436 Cell Lines	Both MMTV-Myc and MMTV-Met transgenic mice  BRCA1 mutation mice PDX models

We are committed to collaborating with healthcare providers and researchers to drive meaningful progress in this critical area of breast cancer management. By collaborating with Alfa Cytology, clients gain access to a comprehensive suite of services tailored to the unique needs of TNBC research and therapeutic development. If you are interested in our service, please contact us.